Viking Therapeutics, Inc. VKTX
FY2025 in six numbers
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (26, from the latest 10-K and 10-Q)
- EPS (ttm)
- -5.42
- Sales (ttm)
- 0
- Net income (ttm)
- -627.2M
- Sales growth
- -
- EPS growth
- -
- Sales Q/Q
- -
- Free cash flow
- -
- Gross margin
- -
- Oper. margin
- -
- Net margin
- -
- FCF margin
- -
- ROE
- -106.6%
- ROA
- -64.2%
- R&D / sales
- -
- Dividend
- -
- Debt/Eq
- -
- Curr. ratio
- 7.27
- Cash
- 677.6M
- Op. cash flow (ttm)
- -462.6M
- Quick ratio
- 7.27
- Shares out.
- 127.5M
- Shares Y/Y
- +3.3%
- Book / share
- 4.62
- Cash / share
- 5.31
- Sales / share
- 0.00
- Asset turnover
- 0.00
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2016 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $639.1M
- = Tangible book value $639.1M
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
VKTX against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics, Inc. | $0 | - | - | - | -106.6% | - | - |
| ROIV Roivant Sciences Ltd. | $41.1M | -71.6% | - | -838.2% | -8.6% | -81.2% | - |
| IDYA IDEAYA Biosciences, Inc. | $36.5M | - | - | - | -38.5% | -957.4% | - |
| CRSP CRISPR Therapeutics AG | $25.2M | -90.6% | - | - | -27.7% | - | 0.36 |
| CGON CG Oncology, Inc. | $6.2M | +255% | - | - | -24.0% | - | 0.00 |
| SRRK Scholar Rock Holding Corp | $570K | - | - | - | - | - | 1.16 |
Profitability
-
Return on equity below 15%-106.6%
-
A profit in 0 of 10 years
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
VKTX's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D | 9.0M | 13.7M | 19.0M | 23.6M | 31.9M | 45.0M | 54.2M | 63.8M | 101.6M | 345.0M |
| SG&A | 4.8M | 5.3M | 7.1M | 9.1M | 10.7M | 10.7M | 16.1M | 37.0M | 49.3M | 48.4M |
| Operating income | -13.8M | -19.1M | -26.2M | -32.7M | -42.7M | -55.7M | -70.4M | -100.8M | -150.9M | -393.3M |
| Interest expense | - | 123K | 81K | - | - | - | - | - | - | - |
| Pretax income | - | - | - | - | - | - | - | -85.9M | -110.0M | -359.6M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 2K | 1K | 1K | 1K | 1K |
| Net income | -14.7M | -20.6M | -22.1M | -25.8M | -39.5M | -55.0M | -68.9M | -85.9M | -110.0M | -359.6M |
| EPS (diluted) | -0.90 | -0.79 | -0.38 | -0.36 | -0.54 | -0.71 | -0.90 | -0.91 | -1.01 | -3.19 |
| Diluted shares | - | - | - | - | - | 77.2M | 76.8M | 94.3M | 109.0M | 112.7M |
Balance sheet
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 3.1M | 9.0M | 24.8M | 8.4M | 29.1M | 26.4M | 36.6M | 55.5M | 26.7M | 165.8M |
| Short-term investments | - | 11.6M | 276.7M | 267.3M | 219.3M | 175.7M | 118.9M | 306.6M | 875.9M | 539.9M |
| Current assets | 14.0M | 21.9M | 302.1M | 283.5M | 256.1M | 210.5M | 167.0M | 367.2M | 907.2M | 715.6M |
| Total assets | 14.5M | 22.1M | 302.3M | 284.3M | 256.5M | 210.7M | 168.5M | 368.5M | 908.3M | 715.7M |
| Accounts payable | 1.2M | 1.5M | 959K | 2.4M | 4.0M | 1.4M | 8.5M | 7.5M | 9.8M | 53.3M |
| Current liabilities | 6.5M | 8.7M | 4.5M | 6.8M | 12.1M | 8.8M | 21.9M | 19.1M | 27.4M | 76.7M |
| Total liabilities | 6.5M | 8.7M | 4.6M | 7.1M | 12.2M | 8.8M | 23.2M | 20.1M | 28.0M | 76.7M |
| Shareholders' equity | 8.0M | 13.5M | 297.8M | 277.1M | 244.3M | 201.9M | 145.3M | 348.4M | 880.3M | 639.1M |
| Retained earnings | -60.3M | -80.9M | -102.9M | -128.7M | -168.2M | -223.2M | -292.0M | -377.9M | -487.9M | -847.5M |
Cash flow
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -11.1M | -14.8M | -18.8M | -24.8M | -21.8M | -47.6M | -48.4M | -73.4M | -87.8M | -278.7M |
| Stock-based pay (added back) | 1.8M | 1.5M | 2.6M | 3.7M | 5.8M | 6.1M | 8.7M | 16.8M | 29.7M | 40.8M |
| Buybacks | 229 | - | - | - | - | - | 6.8M | - | - | - |
| Investing cash flow | 3.0M | -1.7M | -265.7M | 7.5M | 41.6M | 38.0M | 54.8M | -179.1M | -553.4M | 341.4M |
| Financing cash flow | 10.3M | 22.4M | 300.3M | 887K | 950K | 6.9M | 4.2M | 271.4M | 612.5M | 76.4M |
Stock-based pay and leases
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 1.8M | 1.5M | 2.6M | 3.7M | 5.8M | 6.1M | 8.7M | 16.8M | 29.7M | 40.8M |
| Operating lease cost | - | - | - | - | 319K | 320K | - | - | - | - |
| Right-of-use assets | - | - | - | 598K | 321K | 25K | 1.4M | 1.1M | 1.0M | 85K |
| Operating lease liabilities | - | - | - | 662K | 359K | 29K | 1.6M | 1.3M | 1.1M | 137K |
| Finance lease liabilities | - | - | 0 | - | - | - | - | - | - | - |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VKTX/export.csv") into a cell.